Living with moderate to severe eczema is hard enough, but a new US Food and Drug Administration (FDA) decision just made managing it a little easier. The FDA has approved an every-8-week dosing schedule for EBGLYSS (lebrikizumab), a biologic medication used to treat adults and adolescents 12 and older with moderate to severe eczema or atopic dermatitis (AD).
As reported by Dermatology Times, the approval expands dosing options for the medication, which was previously approved with a once-monthly maintenance schedule. With the new regimen, patients who qualify may keep their eczema under control with as few as six injections per year following the initial treatment period.
Ahead, we’re diving deeper into what the new approval means, and who it applies to.
What the FDA Approval Means for Patients
The FDA’s decision was based on long-term clinical data showing patients were able to keep their eczema under control with the extended dosing schedule, with no new safety concerns identified. The data came from patients who had previously participated in multiple clinical trials, including phase 2 and 3 studies, an adolescent study and a VA study—all of whom received maintenance dosing of lebrikizumab 250 mg every four weeks or every eight weeks over a 32-week period, regardless of their prior dosing schedule or treatment response at the start of the extension.
The safety profile was reassuring. No new safety signals emerged during the extension period, and no patients stopped treatment due to adverse events. The most commonly reported side effects, occurring in at least 1 percent of patients, were conjunctivitis, injection-site reactions and herpes zoster.
Why Fewer Injections Matter
Lebrikizumab, originally approved by the FDA in 2024, is a monoclonal antibody that works by targeting and neutralizing interleukin (IL)-13, a protein that plays a key role in driving eczema flares. By blocking IL-13, the drug helps interrupt the inflammatory cycle behind chronic itching and skin irritation.
For those starting the medication, the dosing regimen begins with a 500-mg loading dose administered as two 250-mg injections at weeks 0 and 2. Patients then receive 250 mg every two weeks through week 16, or later until an adequate clinical response is achieved. Following that initial period, maintenance treatment may be administered every four weeks or every eight weeks.
The clinical backing is substantial. The phase 3 development program for lebrikizumab has included more than 1,600 patients across seven key global studies, evaluating the therapy across a range of patients, including adolescents, patients with skin of color, those using it alongside topical corticosteroids and those previously treated with dupilumab.
What Dermatologists Want You to Know
“Today’s approval builds on EBGLYSS’ established long-term durability, with a new option for one maintenance dose every 8 weeks. For people living with moderate to severe atopic dermatitis, that means a treatment they only need to take as few as 6 times a year—without prescription topicals from the start,” said Adrienne Brown, executive vice president and president of Lilly Immunology. “EBGLYSS now gives patients the opportunity to flare less and live their lives with fewer interruptions from atopic dermatitis.”
Chicago dermatologist Peter Lio, MD, who helped author the clinical study, described the approval as an “important moment” for patients managing chronic disease. “This new dosing regimen without mandatory topicals gives patients a new option to manage their condition based on individual needs. It’s about meeting patients where they are in their lives.”
Yale School of Medicine dermatologist Christopher G. Bunick, MD, associate professor of dermatology and editor in chief of Dermatology Times, also weighed in: “AD patients receiving biologic therapies desire less frequent dosing regimens, especially when their skin is clear and itch controlled. FDA approval of lebrikizumab for use every 8 weeks as a maintenance regimen is welcome news, giving dermatologists and patients more flexibility in how they manage AD. Every 8 weeks maintenance dosing for lebrikizumab is a significant differentiator among IL-13 and IL-4R targeted biologics and must be considered in shared clinical decision making.”
What This Means for You
For people living with moderate to severe eczema, treatment doesn’t just mean clearer skin. It often means fewer flares, better sleep and less disruption to daily life. With as few as six injections a year now an option, this approval gives patients and their dermatologists another meaningful way to personalize long-term care.
